Published in Gynecol Oncol on June 01, 2001
Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab (2002) 1.47
Protein kinase Calpha: disease regulator and therapeutic target. Trends Pharmacol Sci (2009) 1.25
Analysis of protein kinase C delta (PKC delta) expression in endometrial tumors. Hum Pathol (2007) 1.01
Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix. Mol Cancer Res (2009) 0.93
The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer (2014) 0.90
Protein kinase C alpha-dependent signaling mediates endometrial cancer cell growth and tumorigenesis. Int J Cancer (2009) 0.89
PKCα and ERβ Are Associated with Triple-Negative Breast Cancers in African American and Caucasian Patients. Int J Breast Cancer (2012) 0.83
The effects of PGC-1α on the proliferation and energy metabolism of malignant endometrial cancer cells. Onco Targets Ther (2015) 0.82
Targeting Protein Kinase C Downstream of Growth Factor and Adhesion Signalling. Cancers (Basel) (2015) 0.77
Low expression of PKCα and high expression of KRAS predict poor prognosis in patients with colorectal cancer. Oncol Lett (2016) 0.75
A community-based study of chronic fatigue syndrome. Arch Intern Med (1999) 6.04
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med (1992) 3.54
Oncologists' reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study. J Clin Oncol (1991) 3.50
Assessing the impact of total quality management and organizational culture on multiple outcomes of care for coronary artery bypass graft surgery patients. Med Care (2000) 3.17
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol (1977) 3.03
The pharmacology and clinical uses of tamoxifen. Pharmacol Ther (1984) 3.02
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst (1998) 2.88
A multicenter clinical investigation employing ethinyl estradiol combined with dl-norgestrel as postcoital contraceptive agent. Fertil Steril (1982) 2.80
Histopathologic findings of duodenal biopsy specimens in HIV-infected patients with and without diarrhea and malabsorption. Am J Clin Pathol (1992) 2.74
A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res (1993) 2.65
Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev (1998) 2.50
Temporal and biomechanical characteristics of oropharyngeal swallow in younger and older men. J Speech Lang Hear Res (2000) 2.28
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
The chromosome constitution of 1000 human spermatozoa. Hum Genet (1983) 2.21
Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst (1992) 2.19
MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res (1997) 2.12
Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol (1996) 2.07
Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med (1992) 2.06
Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos (1991) 2.04
Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst (1990) 1.97
Chromosomal analysis of sperm from men with idiopathic infertility using sperm karyotyping and fluorescence in situ hybridization. Fertil Steril (1995) 1.93
Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer (2003) 1.83
Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res (1988) 1.80
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res (1996) 1.79
Laparoscopically assisted vaginal hysterectomy in a university hospital: report of 82 cases and comparison with abdominal and vaginal hysterectomy. Am J Obstet Gynecol (1993) 1.78
Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res (1990) 1.78
Pharyngeal effects of bolus volume, viscosity, and temperature in patients with dysphagia resulting from neurologic impairment and in normal subjects. J Speech Hear Res (1994) 1.76
Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst (1996) 1.76
Biochemical pharmacology of antiestrogen action. Pharmacol Rev (1984) 1.74
Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res (2000) 1.73
Incidence and patient characteristics associated with silent aspiration in the acute care setting. Dysphagia (1999) 1.71
Closure mechanisms of laryngeal vestibule during swallow. Am J Physiol (1992) 1.67
Functional results of primary closure vs flaps in oropharyngeal reconstruction: a prospective study of speech and swallowing. Arch Otolaryngol Head Neck Surg (1998) 1.66
Prevention of barium aspiration during videofluoroscopic swallowing studies: value of change in posture. AJR Am J Roentgenol (1993) 1.66
Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat Rep (1976) 1.63
Chin-down posture effect on aspiration in dysphagic patients. Arch Phys Med Rehabil (1993) 1.60
Effects of postural change on aspiration in head and neck surgical patients. Otolaryngol Head Neck Surg (1994) 1.59
Changes in pharyngeal dimensions effected by chin tuck. Arch Phys Med Rehabil (1993) 1.56
Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med (1991) 1.55
Effects of bolus volume, viscosity, and repeated swallows in nonstroke subjects and stroke patients. Arch Phys Med Rehabil (1993) 1.53
Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells. J Biol Chem (1994) 1.53
Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res (1987) 1.52
Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer (1976) 1.50
Markedly elevated maternal serum alpha-fetoprotein associated with a normal fetus and choriocarcinoma of the placenta. Obstet Gynecol (1990) 1.50
A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost (1993) 1.50
Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat (1982) 1.48
Variation in the frequency and type of sperm chromosomal abnormalities among normal men. Hum Genet (1987) 1.46
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res (1988) 1.44
Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood (1996) 1.44
Tamoxifen and contralateral breast cancer. J Am Coll Surg (1999) 1.41
Human immunodeficiency virus-related lymphomas: a possible association between tumor proliferation, lack of ploidy anomalies, and immune deficiency. J Clin Oncol (1991) 1.39
An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol (1992) 1.39
Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol (1987) 1.38
Age variation in the association between angiographic coronary disease and angina from the Coronary Artery Surgery Study (CASS) Int J Cardiol (1989) 1.37
Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep (1981) 1.37
Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry (2002) 1.36
A risk-benefit assessment of tamoxifen therapy. Drug Saf (1993) 1.34
Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut (1997) 1.32
Inappropriate use and unmet need in paramedic and nonparamedic ambulance systems. Ann Emerg Med (1987) 1.32
Swallowing and tongue function following treatment for oral and oropharyngeal cancer. J Speech Lang Hear Res (2000) 1.32
Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol (2005) 1.31
Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat (1988) 1.29
Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery (1999) 1.28
Tamoxifen as an anti-tumour agent: effect on oestrogen binding. J Endocrinol (1976) 1.27
Uterine arteriovenous malformations: primary treatment with therapeutic embolization. J Vasc Interv Radiol (1991) 1.27
Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer (1980) 1.27
An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res (1995) 1.23
High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol (1989) 1.21
The effect of age on the frequency of sperm chromosomal abnormalities in normal men. Am J Hum Genet (1987) 1.21
Speech and swallowing in irradiated and nonirradiated postsurgical oral cancer patients. Otolaryngol Head Neck Surg (1998) 1.21
Summer sun exposure: knowledge, attitudes, and behaviors of Midwest adolescents. Prev Med (1997) 1.20
Super-supraglottic swallow in irradiated head and neck cancer patients. Head Neck (1997) 1.20
Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res (1988) 1.19
Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem (1988) 1.19
Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat. Mol Cell Endocrinol (1977) 1.18
Speech and swallowing function after oral and oropharyngeal resections: one-year follow-up. Head Neck (1994) 1.17
Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res (1989) 1.17
Impaired deglutitive airway protection: a videofluoroscopic analysis of severity and mechanism. Gastroenterology (1997) 1.17
Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships. Br J Pharmacol (1980) 1.16
Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett (1995) 1.16
Normal swallowing physiology as viewed by videofluoroscopy and videoendoscopy. Folia Phoniatr Logop (1999) 1.15
Structure-activity relationships of estrogens. Environ Health Perspect (1985) 1.15
Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol. Breast Cancer Res Treat (1987) 1.13
Management of twin pregnancies consisting of a complete hydatidiform mole and normal fetus. Obstet Gynecol (1998) 1.13
Natural history of hydatidiform mole after primary evacuation. Am J Obstet Gynecol (1983) 1.13
Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response. J Endocrinol (1976) 1.12
Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer (1996) 1.12
Skin cancer control practices among physicians in a university general medicine practice. J Gen Intern Med (1995) 1.11
Socioeconomic status and attitudes of 51 patients with giant basal and squamous cell carcinoma and paired controls. Arch Dermatol (1995) 1.10
Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol (1991) 1.10
Speech and swallow function after tonsil/base of tongue resection with primary closure. J Speech Hear Res (1993) 1.08
Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer (1975) 1.06
Reliability of steroid hormone receptor assays: an international study. Eur J Cancer Clin Oncol (1983) 1.06
Aneuploidy in human sperm: the use of multicolor FISH to test various theories of nondisjunction. Am J Hum Genet (1996) 1.06
Multicolor fluorescence in situ hybridization analysis of aneuploidy and diploidy frequencies in 225,846 sperm from 10 normal men. Biol Reprod (1996) 1.05
Pretreatment swallowing function in patients with head and neck cancer. Head Neck (2000) 1.05
Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. Mol Pharmacol (1990) 1.05
Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol (2000) 1.05